LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing
Objective: Report on the non-clinical in vivo pharmacokinetic and pharmacodynamic biomarker response to PROteolysis TArgeting Chimera (PROTAC®) molecules designed to induce degradation of leucine rich…Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson’s disease treated with foslevodopa/foscarbidopa subcutaneous 24 hour infusion
Objective: To evaluate whether treatment with foslevodopa/foscarbidopa (LDP/CDP), a continuous (24‑hour/day) subcutaneous infusion of carbidopa/levodopa prodrugs, improves motor fluctuations and quality of life (QoL) in…Axial impairment and bradykinesia are related to increased CSF sTREM2, a neuroinflammation biomarker, in Parkinson’s disease
Objective: To explore the association between Parkinson’s disease (PD) motor symptoms and CSF biomarkers for neuroinflammation and neurodegeneration. Background: Previous in vivo and post mortem…Istradefylline therapy for PD plus oromandibular dystonia
Objective: To clarify the dopaminergic system link between parkinson's disease (PD) and oromadibular dystonias (OMDy) co-occur, and the effect of istradefylline (IST) therapy. Background: OMDy are…Transcriptional dysregulation in iPSC-derived neurons from patients with X-linked dystonia-parkinsonism
Objective: We pursue to identify dysregulated cellular pathways underlying X-linked dystonia-parkinsonism (XDP) by transcriptome profiling of induced pluripotent stem cell (iPSC)-derived neuronal cultures from XDP…Widespread Synuclein pathology in hyposmics precedes dopamine transporter deficit in PARS
Objective: The Parkinson Associated Risk syndrome (PARS) study is designed to identify a Parkinson disease (PD) biomarker/clinical marker derived cohort enriched to develop typical symptoms…Continuous algorithmic insights into PD motor symptoms and individual treatment response
Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study
Objective: Determine the efficacy, safety, and tolerability of ND0612 versus oral immediate-release levodopa/carbidopa (IR-LD/CD) in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background: ND0612…Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.
Objective: To conduct a case-control study in single, comprehensive movement disorder center in Seoul. Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease…Bone Health in Parkinson’s Disease
Objective: Optimise bone health in people with Parkinson’s Disease Background: People with Parkinson’s Disease (PD) have an increased risk of osteoporosis and associated fractures due…
- « Previous Page
- 1
- …
- 611
- 612
- 613
- 614
- 615
- …
- 1942
- Next Page »